Who is sponsoring NCT00387907?

NCT00387907 is sponsored by Sanofi.

What condition does NCT00387907 study?

NCT00387907 studies Advanced Breast Cancer, Breast Cancer, Metastatic Breast Cancer.

What drugs are being tested in NCT00387907?

Interventions: larotaxel (XRP9881), trastuzumab.

What is the status of NCT00387907?

NCT00387907 is currently COMPLETED.

Last reviewed 2016-04-06 · How we verify

Open Label, Uncontrolled, Study of XRP9881 (Larotaxel) in Combination With Weekly Trastuzumab (Herceptin®) in Patients With HER2 Positive Metastatic Breast Cancer (MBC)

NCT00387907 Phase 2 COMPLETED

The purpose of this study is to evaluate the anti-tumor activity of the combination of experimental drug (larotaxel) when combined with Herceptin® in patients with advanced breast cancer. Anti-tumor activity will be determined by looking at changes in tumor size on CT or MRI scans. Additional goals of this study are to look at patient safety, to determine how long the study drugs (larotaxel and Herceptin®) stay in the patient's body and what effects the study medications may have on each other, and to find out how long patients remain cancer free on this study treatment.

Details

Lead sponsor	Sanofi
Phase	Phase 2
Status	COMPLETED
Enrolment	6
Start date	2006-10
Completion	2008-03

Conditions

Advanced Breast Cancer
Breast Cancer
Metastatic Breast Cancer

Interventions

larotaxel (XRP9881)
trastuzumab

Primary outcomes

Tumor response measured — every 2 cycles during treatment phase

Countries

United States